Tag Press Release

Lipotype presents the awardees of the Lipidomics Forum 2018

We proudly present the winners of best poster and best scientific talk award at the Lipidomics Forum 2018.


A short history of the Lipidomics Forum
The Lipidomics Forum is a joint effort of the ISAS Dortmund and the Research Center Borstel. The annual symposium is a series of conferences on lipid biology and lipidomics to provide a platform for international acknowledged scientists, students, and young researchers to interact. It does not only cover current research highlights but also offers tutorials on selected methodical topics.

The Lipidomics Forum has become a home for Lipotype. Besides a shared scientific background, we strive for the same goals such as global scientific excellence and exchange. This is why Lipotype began attending and supporting through awards the conference many years ago.


The awardees
The best poster award was won by Bing Peng (middle). She researches blood platelets and their lipid composition which is critical for platelet integrity and functionality. She could show, that the lipidome changes upon platelet activation. Congrats, Bing Peng!

The best scientific talk award was won by Marcus Höring (right). His work aims at the intestinal lipid metabolism and the influence of gut microbia. He made use of isotope labeled fatty acids to achieve that. Congrat, Marcus Höring!

Ronny Herzog
Dr. Ronny Herzog, Head of Software Development and IT-Infrastructure, and the awardees.

Dominik Schwudke (top left) and Robert Ahrends (bottom left) have been organizing the Lipidomics Forum since its beginning. To say thank you, we gifted both a rafting weekend. We are certain, they will have as much fun as we have with our lipid raft.


Resources

Press Release: Lipotype presents the awardees of the Lipidomics Forum 2018

Abstract book of the Lipidomics Forum 2018

Lipidomics Forum 2018


Follow us on LinkedIn, Twitter or Facebook, and subscribe to our newsletter to stay updated on lipids and lipidomics!

New White Paper “Unlocking the Power of Multiomics”

Multiomics approaches harness synergies and eliminate shortcomings to effectively deliver what one omics science alone cannot achieve. Lipotype’s new white paper “Unlocking the Power of Multiomics” highlights why combining genomics with lipidomics makes for a great omics pair.


Genomics for genes, lipidomics for lipids
Being major players in cardiovascular disease research, genomics and lipidomics are perfectly suited for a joint multiomics approach. It matches the capacity to identify genetic predestinations with one or multiple snapshots of the lipid metabolic status.

Linking genotype with phenotype will be critical when it comes to clinical diagnostics and to the goal of identifying the onsets of a disease.


From genotype to phenotype: interconnected disease risk factors
In this study, a large number of SNPs (single-nucleotide polymorphisms) from genomes was drawn. They were then correlated with corresponding lipid species levels from human blood plasma. The blood plasma has been analyzed with Lipotype Shotgun Lipidomics technology. The most important findings are the following.

First, the heritability of lipid species levels was quantified from the SNP correlations. Second, genetic predispositions influencing lipid species levels provide useful information for cardiovascular disease risk predictions. And third, lipidomics yields greater statistical power to identify SNPs with direct roles in lipid metabolism. Lipidomics outperforms traditional lipid panel measures used in clinical routine.


Resources

Lipotype White Paper: Unlocking the Power of Multiomics

Press release: Unlocking the Power of Multiomics – Lipotype releases new Multiomics White Paper


Follow us on LinkedIn, Twitter or Facebook, and subscribe to our newsletter to stay updated on lipids and lipidomics!

Press Release: Lipotype and Lipoid celebrate their joint IFSCC 2018 Poster Success

Lipotype and Lipoid presented a joint poster featuring the core findings of their skin lipidome research at IFSCC 2018 in Munich. Overwhelmingly positive feedback resulted in placing the poster among the top 10 of all IFSCC 2018 posters.


A successful congress and a great poster
The International Federation of Societies of Cosmetic Chemists is dedicated to international cooperation in cosmetic science and technology. This year’s congress was about “Cosmetics: Science for Beauty and Lifestyle”.

Lipotype and Lipoid chose the IFSCC to present their findings as the congress focuses on exploring what modern society wants from cosmetics and dermatology. This represents both companies’ consumer oriented research best, which was confirmed on-site by the great feedback of those who visited the poster. Ultimately, the IFSCC committee chose to rank the joint poster of Lipotype and Lipoid among the top 10 of all IFSCC 2018 posters.


The project in short
Lipoid conducted this novel study to investigate skin penetration properties of dermal formulations based on hydrogenated phospholipids. For the first time, the quantitative analysis of both exogenous phospholipids and endogenous skin lipids within a single measurement was demonstrated. The results confirm the properties of hydrogenated phospholipids to penetrate and accumulate in upper epidermal layers. Based on these findings, Lipoid will conduct further investigations to improve delivery and fixation of cosmetic actives.


About Lipoid
Founded over 40 years ago, Lipoid is leading in the development and industrial production of high quality lecithin and phospholipids not only for the pharmaceutical, but also for the cosmetic and dietetic industry. Lipoid is the only company worldwide offering the whole range of natural and synthetic phospholipids in industrial scale. Environmental protection and sustainability determines the company’s strategy within all phases of the value chain. This long-standing expertise, in combination with the exceptional quality of the products enables the customers to develop and market innovative products for the benefit of the general public.


Resources

Press release: IFSCC 2018 poster success – Joint poster selected Top 10 of all IFSCC posters

IFSCC 2018 poster: The effect of saturated phospholipids on human skin as assessed by shotgun lipidomic analysis

IFSCC 2018 poster ranking

Customer reference: Lipid analysis for skin penetration properties of saturated phospholipids


Follow us on LinkedIn, Twitter or Facebook, and subscribe to our newsletter to stay updated on lipids and lipidomics!

Lipotype’s customer Lyomark Pharma announces partnership

Lyomark Pharma, a customer of Lipotype, announces a partnership with Aerogen Pharma to develop an inhaled surfactant for the treatment of preterm infants with Respiratory Distress Syndrome (RDS). At the same time clinical trials with the new delivery system have been initiated and the first patients have been recruited. Read more in the press release of Lyomark and Aerogen:


Read more in the press release of Lyomark and Aerogen here:
Aerogen Pharma and Lyomark Pharma partner to develop inhaled surfactant, begin a Phase 2 clinical trial

Lipidomics paves the way to groundbreaking scientific discoveries

VIB’s Technology Watch team has been active for almost a decade, continuously analyzing the potential of emerging technologies and mediating researchers’ access to them. By expanding VIB’s network of technology suppliers, purchasing licenses and negotiating business partnerships, the Tech Watch team enables VIB scientists to have privileged access to cutting-edge scientific innovations. One example comes in the form of a powerful lipidomics research tool made available to VIB scientists through a collaboration with Lipotype, a Max-Planck spin-off and key service provider. Since 2015, Lipotype technology has been a crucial factor in several major breakthroughs in multiple life sciences domains.

The benefits of a dedicated lipidomics collaborator
Lipidomics, or the analysis, identification and quantification of lipids, has important applications in basic and clinical research, as well as in the nutrition, cosmetics and personalized healthcare industries. Using Lipotype’s Shotgun Lipidomics Technology, researchers can rapidly analyze large samples at reasonable prices, benefiting from the ultra-broad coverage and absolute quantification of lipids enabled by this technology.

Mark Veugelers (VIB Tech Watch): “The Tech Watch team, in close collaboration with VIB group leaders, is constantly on the lookout for new technologies that can have a major impact on our research. The Lipidomics services Lipotype offers is a good example. But identification of a novel technology with potential isn’t enough to produce breakthrough results. Key in the process is the hands-on experience of VIB scientists when evaluating the potential of these novel technology opportunities.

Oliver Uecke (Lipotype): “Tech Watch at VIB is a fantastic instrument to support technology transfer.  It’s a win-win situation for all parties involved: VIB researchers get access to innovative technologies early on, while technology providers have the tech watch team as single entry point to address the VIB collective of researchers. VIB profits from providing their researchers with means to generate cutting edge research results and with an improved basis for licensing and spin-off creation.”

Better tech integration, impactful results
After just two years of collaboration, VIB scientists working with Lipotype have published three papers in high-impact academic journals. This demonstrates the fact that partnerships between VIB and specialized tech service providers and the integration of new innovations into VIB research leads to more and faster discoveries.

Prof. Wim Annaert (VIB-KU Leuven): “Lipotype’s Shotgun technology was critical to our recent paper on a new approach to analyzing subcellular dysfunction. Our next challenge is now to integrate lipidomics with proteomics data to better understand what goes on at the level of a single subcellular compartment for instance in a disease context.”
(relevant publication: A novel approach to analyze lysosomal dysfunctions through subcellular proteomics and lipidomics: the case of NPC1 deficiency, Tharkeshwar et al., Scientific Reports 2017)

Prof. Patrik Verstreken (VIB-KU Leuven): “My team recently made groundbreaking discoveries related to mitochondrial defects in Parkinson’s Disease. Tech Watch – and access to Lipotype tech in particular – were essential to these findings.”
(relevant publication: Cardiolipin promotes electron transport between ubiquinone and complex I to rescue PINK1 deficiency, Vos et al., J Cell Biol 2017)

Prof. Rose Goodchild (VIB-KU Leuven): “Tech Watch funding significantly boosted our confidence in collaborating with Lipotype for our work on cellular lipid metabolism. Lipidomics is a key emerging technology that we don’t have in-house, and our access to it – especially when it comes to molecular and cellular research – adds huge value to our projects.”
(relevant publication: Torsins Are Essential Regulators of Cellular Lipid Metabolism, Gonzalez et al., Developmental Cell 2016)

Read the full press release here
 Open Adobe PDF Version
 Download the Microsoft Word Version

 


About Lipotype

Lipotype is a spin-off company from the Kai Simons and Andrej Shevchenko labs of the world-renowned Max-Planck-Institute of Molecular Cell Biology and Genetics in Dresden, Germany. Drawing on many years of cutting edge research experience, Lipotype delivers comprehensive, absolutely quantitative lipid analysis services for clinical and biological samples on a high-throughput scale.

Lipotype offers high quality lipid analysis services for a wide range of customers and applications including biomarker identification for clinical researchers, pharma and biotech companies, functional food development for the food industry, as well as for the small-scale profiling needs of academic researchers.


Follow us on  LinkedIn Twitter or  subscribe to our newsletter

Largest skin lipidomics study provides a basis for personalized cosmetics

The largest lipidomics study to date analyzing skin lipids in more than 250 skin samples has been published in “Scientific Reports” (Sadowski T. et al. “Large-scale human skin lipidomics by quantitative, high-throughput shotgun mass spectrometry.” Scientific Reports 2017, doi: 10.1038/srep43761). The study applied a novel Skin Lipidomics Technology Platform developed by Lipotype GmbH, a German Max-Planck-Institute spin-off. Results showed that the skin lipidome varies with respect to sampling depth, site, age and subject. This variation seems to be driven, mainly by secretion of sebaceous lipids and this finding could have an intriguing impact on the design of cosmetic products. Results also reveal a high inter-individual variation of the lipid profile of each person, which could become the basis for the development of personalized cosmetics.  Read more


Discover how skin lipidomics can be applied for your research and product development and get the White Paper.


Meet us at in-cosmetics in London (04th -06th of April 2017): Schedule an individual appointment

 

Launch of BEAt-DKD

An Innovative Medicines Initiative (IMI) Project for Precision Medicine in Diabetic Kidney Disease

with Lipotype as project partner

 

BEAt-DKD (“Biomarker Enterprise to Attack Diabetic Kidney Disease”), a unique public private partnership funded by the Innovative Medicines Initiative (IMI), member companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Juvenile Diabetes Research Foundation (JDRF) and the state of Switzerland has announced the launch of a 5-­­year project (total budget 28.9 Million Euro) with the aim to improve prevention and management of Diabetes Kidney Disease (DKD).

Leading experts from 21 academic institutions, 6 EFPIA pharmaceutical companies, 1 biotech company and JDRF launched BEAt-DKD to provide a holistic systems medicine view of the pathogenesis and heterogeneity of DKD, with the goal to identify targetable mechanisms and pathways underlying initiation and progression of DKD, as well as to identify and validate biomarkers of disease progression and treatment responses, representing first steps towards precision medicine in DKD. Lipotype is project partner in this consortium.

Please download the official press release of the BEAt-DKD consortium here

robert_koch_medal_gold_medal_161103.jpg

Robert Koch Gold Medal 2016 to Kai Simons

Press release

Berlin/Dresden, 4 November 2016: Kai Simons, founding director of the Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG) and managing director of Lipotype GmbH, receives the Robert Koch Medal in Gold for his lifetime achievements, in particular for his characterization of membrane-forming lipids and the development of the lipid raft concept. The Award Ceremony takes place on Friday, November 4th 2016 at the Berlin-Brandenburg Academy of Sciences and Humanities.


Read the full press release here

 Open PDF: EnglishDeutsch

 Download Microsoft Word File: English / Deutsch

 

Picture of the award ceremony

picture-kai-robert-koch-award

During the award ceremony at the Berlin-Brandenburg Academy of Sciences and Humanities, Kai Simons received the award from Annette Widmann-Mauz, Parliamentary State Secretary, and Dr. Hubertus Erlen, Chairman of the Board of Directors of the Robert Koch Foundation.

Photo: David Ausserhofer

Novel skin lipidomics for cosmetic and dermatological applications

Lipotype GmbH, a German Max-Planck spin-off company, launched its novel Lipotype Shotgun Skin Lipidomics Technology and offers lipid analysis services for applications such as cosmetic claim support, topical drug development, efficacy testing for dermatological pharmacology and the cosmetic industry.

High-throughput skin lipidomics with ultra-broad fully quantitative coverage
Until recently, investigating skin lipidomes was not a trivial task. On one hand, the analytical method needs to have coverage broad enough to encompass the variety of skin lipids, and a throughput allowing for statistically relevant studies. On the other hand the method should be compatible with a convenient sampling technique such as tape stripping. These prerequisites are now met in the Lipotype Shotgun Skin Lipidomics Technology platform as explained by Prof. Kai Simons, CEO of Lipotype: “We offer unprecedented throughput of hundreds of samples, absolutely quantified with broad coverage of ceramides, triglycerides and other lipids, and this is all available for samples collected by super-easy tape stripping.” The development of Lipotype Skin Lipidomics was supported by the German Central Innovation Programme for SMEs.

Applications of skin lipidomics
With tools such as Lipotype Skin Lipidomics it is now easy to investigate how the healthy skin lipidome is composed, how it changes in diseases or upon intervention with a drug or a cosmetic product. This lipidomic data can be used for cosmetic claim support, topical drug development and efficacy testing. “We are excited about new possibilities to include skin lipidomics in the product development process of cosmetics companies as well as for biomarker identification for dermatology”, says Dr. Oliver Uecke, Head of Business Development and Finance at Lipotype GmbH.

Read the full press release here
Open Adobe PDF Version
 Download the Microsoft Word Version


Meet us at cosmetics360 in Paris (13.-14.10.2016)

Schedule an individual appointment and  contact us


“HIGHLIGHTS” of our novel Lipotype Shotgun Skin Lipidomics Technology

Read more here


 

Follow us on LinkedIn, Twitter or subscribe to our newsletter

Launch of RHAPSODY

An Innovative Medicines Initiative Project for Precision Therapy and Prevention of Diabetes with Lipotype as project partner

 

RHAPSODY (“Risk Assessment and ProgreSsiOn of DIabetes”), a public private consortium funded by the Innovative Medicines Initiative (IMI) and EFPIA Companies with contributions from academic institutions, has announced the launch of a project focused on assessing the risk of progression of pre-diabetes to overt diabetes and of rapid deterioration of type 2 diabetes (T2D), a pandemic disease, which currently affects 285 million people worldwide. Leading European experts from 20 academic institutions, 4 EFPIA pharmaceutical organizations and 2 biotech companies officially launched the IMI project RHAPSODY. Lipotype is project partner in this consortium. Combining new and existing data with the expertise of its partners, RHAPSODY will develop novel biomarkers to refine diagnosis leading to better patient stratification, promote prevention, and support innovative drug discovery for personalized management of diabetes.

Please read the official press release of the RHAPSODY consortium here